Targeting the spliceosome for cutaneous squamous cell carcinoma therapy: a role for c-MYC and wild-type p53 in determining the degree of tumour selectivity

We show that suppression of the spliceosome has potential for the treatment of cutaneous squamous cell carcinoma (cSCC). The small-molecule inhibitors of the spliceosome at the most advanced stage of development target the splicing factor SF3B1/SF3b155. The majority of cSCC cell lines are more sensi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hepburn, Lydia A., McHugh, Angela, Fernandes, Kenneth, Boag, Garry, Proby, Charlotte M., Leigh, Irene M., Saville, Mark K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955416/
https://www.ncbi.nlm.nih.gov/pubmed/29796170
http://dx.doi.org/10.18632/oncotarget.25196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955416/
https://www.ncbi.nlm.nih.gov/pubmed/29796170
http://dx.doi.org/10.18632/oncotarget.25196

Ejemplares similares